



European Commission

Directorate General Enterprise & Industry

Transparency Directive 89/105/EEC:

Transparency of measures relating to pricing and reimbursement of medicinal products

Explanatory part of the "screening" Croatia-Turkey
Chapter 1 – Free movement of goods
Pharmaceutical acquis

Presentation by Christophe Roeland, DG Enterprise & Industry F/5
18 January 2006 - Brussels



Introduction

- Decisions on prices of medicinal products and their reimbursement fall within the responsibility of Member States
- However, national pricing and reimbursement measures may have an impact on market access & free movement of goods
- Necessity to ensure that such measures do not hinder or distort intra-Community trade
- ➔ Harmonised legal instrument to guarantee the transparency of pricing and reimbursement measures

Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion within the scope of national health insurance system (OJ N°40 of 11.2.1989, p. 8)



Objectives of the Directive

- Obtain an overall view of pricing arrangements in each Member State
- Ensure that all interested parties can verify that national pricing and reimbursement measures do not constitute quantitative restrictions on imports or exports, or measures having equivalent effect
- ➔ Procedural framework to facilitate the implementation of, and verification of compliance with, EC Treaty rules on free movement of goods (Article 28 of the Treaty)



Scope of the Directive

- Directive 89/105/EEC applies to any national measure (whether laid down by law, regulation or administrative provision)
 - to control the prices of medicinal products for human use
 - or
 - to restrict the range of medicinal products covered by their national health insurance systems

- The Directive does not affect national policies on pricing and reimbursement of medicinal products, except as far as it is necessary to guarantee the transparency of national systems



Directorate General Enterprise & Industry

Key provisions (1)

Areas covered

Price decisions

(Articles 2 & 3)

- Decisions on initial price
- Decisions to increase price

Reimbursement decisions

(Articles 6 & 7)

- Decisions on inclusion in / exclusion from the list of reimbursed products (positive list)
- Decisions on inclusion in / exclusion from the list of non-reimbursed products (negative list)

Obligations

Strict timeframe

- Rule = 90 days from receipt of application (90 for pricing / 90 days for reimbursement)

Transparent criteria

- Objective and verifiable criteria must be defined and published
- Individual decisions must be motivated in light of these criteria (statement of reasons)

Legal remedies

- Applicants must be informed of the legal remedies available and timeframe to appeal (independent legal body)



Key provisions (2)

Areas covered

Price freeze

(Article 4)

→ If price freeze imposed on all medicinal products or on certain medicinal products

Profit control

(Article 5)

→ If systems of direct or indirect controls on the profitability of marketing auth. holders

Obligations

Regular assessment

→ At least once a year: obligation to carry out a review to determine if economic conditions justify maintaining the price freeze

Derogations

→ Possibility to request a derogation from the price freeze

Specific information on the system

→ Must be published in relevant publication
→ Must be communicated to the Commission



Interpretation by the Court of Justice

- Legal instrument linked to the free movement of goods (one of the fundamental freedoms of the EU)
- Consequently, the European Court of Justice Directive considers that the Directive cannot be interpreted restrictively:
 - The Transparency Directive must be interpreted in light of its objectives, so as to ensure its effectiveness
 - Any national measure to control prices or reimbursement must comply with its provisions
 - Otherwise, the obligations of the Directive could be easily circumvented and its objectives would be jeopardised



Directorate General Enterprise & Industry

Implications

- This broad legal interpretation has important consequences – for example:
 - The Directive applies to measures of a general nature where they amount to a bundle of individual decisions
 - e.g. → List of active substances*
 - Prescription vs. non-prescription medicines*
 - Creation of therapeutic groups*
 - If different levels or categories of reimbursement are established, the transparency requirements of the Directive must be applied to each level or category
 - e.g. → Criteria for each level/category of reimbursement*

- See relevant case law:
 - C-424/99, Commission v. Austria, 27 November 2001
 - C-229/00, Commission v. Finland, 12 June 2003



European Commission

Directorate General Enterprise & Industry

Conclusion

- A key instrument for the functioning of the internal market in medicinal products
- A short, but essential piece of the pharmaceutical acquis



European Commission

Directorate General Enterprise & Industry

Contacts

DG Enterprise and Industry

Unit F/5: Competitiveness of the pharmaceutical industry and Biotechnology

Mr. Christian Siebert, Head of Unit
(+32-2) 296 62 44
christian.siebert@cec.eu.int

Mr. Christophe Roeland, Administrator
(+32-2) 296 72 57
christophe.roeland@cec.eu.int

Mr. Stefaan van der Spiegel, Administrator
(+32-2) 295 54 06
stefaan.van-der-spiegel@cec.eu.int